Therapeutic Advances in Vaccines and Immunotherapy最新文献

{"title":"Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.","authors":"Daniel Mhanna, Bilal Salman, Rawad El Hakim, Lea Aridi, Wissam Abou Ali, Bilal Al Halabi, Vivian Faour, Frederic Harb, Sami Azar, Hilda E Ghadieh","doi":"10.1177/25151355261488241","DOIUrl":"10.1177/25151355261488241","url":null,"abstract":"<p><p>Melanoma has emerged as a major focus of cancer immunotherapy research because of its highly immunogenic nature and responsiveness to immune-based treatments. Therapeutic melanoma vaccines are designed to stimulate tumor-specific immune responses through the delivery of Tumor-Associated Antigens (TAAs), Tumor-Specific Antigens (TSAs), and personalized neoantigens. This narrative review provides an overview of current melanoma vaccine strategies, including peptide-based vaccines, dendritic cell vaccines, nucleic acid-based platforms such as mRNA, DNA, and viral vector vaccines. Recent advances in vaccine engineering and tumor genomics have accelerated the development of personalized neoantigen vaccines capable of targeting mutations unique to individual tumors. In parallel, Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being incorporated into neoantigen identification pipelines to improve epitope prediction and optimize vaccine design. Combination strategies involving Immune Checkpoint Inhibitors (ICIs), particularly anti-PD-1 and anti-CTLA-4 therapies, have further enhanced interest in melanoma vaccines by helping overcome tumor-induced immune suppression and augment T-cell activation. In addition to reviewing vaccine mechanisms and emerging technologies, this manuscript examines the evolving clinical trial landscape through analysis of melanoma vaccine studies registered on ClinicalTrials.gov. Although many studies have reported encouraging safety and immunogenicity findings, challenges related to tumor heterogeneity, immune evasion, biomarker selection, and manufacturing complexity continue to limit widespread clinical implementation. Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy. Collectively, these innovations may help establish melanoma vaccines as an increasingly important component of future personalized cancer immunotherapy strategies.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"14 ","pages":"25151355261488241"},"PeriodicalIF":0.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Exploring the safety and immunogenicity of the VLA15 vaccine among healthy or high-risk population: a systematic review and meta-analysis of randomized controlled trials.","authors":"","doi":"10.1177/25151355261476385","DOIUrl":"https://doi.org/10.1177/25151355261476385","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1177/25151355251387927.].</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"14 ","pages":"25151355261476385"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13476590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and feasibility of vaccination interventions for Indigenous and hard-to-reach populations in Latin America and the Caribbean: a systematic review and meta-analysis.","authors":"Danladi Chiroma Husaini, Shamira Morales, Jing Chun Hung, Leah Eck","doi":"10.1177/25151355261472591","DOIUrl":"10.1177/25151355261472591","url":null,"abstract":"<p><strong>Background: </strong>Persistent vaccination inequities affect Indigenous and hard-to-reach populations in Latin America and the Caribbean (LAC), yet evidence on effective interventions remains fragmented.</p><p><strong>Objectives: </strong>To synthesize evidence on the effectiveness and feasibility of interventions designed to improve vaccination coverage among Indigenous and hard-to-reach populations in LAC.</p><p><strong>Design: </strong>Systematic review and meta-analysis following PRISMA 2020 guidelines.</p><p><strong>Methods: </strong>We searched PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, Google Scholar, and PAHO/WHO repositories for studies published between January 2015 and March 2025. Eligible studies reported primary data on vaccination coverage among Indigenous, rural, migrant, or marginalized populations in LAC. Two independent reviewers performed screening, data extraction, and quality assessment (JBI tools). Random-effects meta-analysis was conducted for comparable outcomes, with subgroup analyses by population and intervention type. Feasibility was assessed across logistical, financial, and cultural domains using an implementation science framework.</p><p><strong>Results: </strong>Of 2750 records, 21 studies met inclusion criteria, representing 10 LAC countries. Interventions included community health worker (CHW) outreach (43%), mobile units (29%), school-based delivery (14%), digital reminders (10%), and culturally tailored campaigns (5%). Meta-analysis of 16 studies showed that individuals receiving interventions were 64% more likely to achieve complete vaccination (risk ratio (RR) = 1.64; 95% confidence interval (CI), 1.32-2.04). Effects were stronger for Indigenous populations (RR = 1.85; 95% CI, 1.42-2.25) than for other rural groups (RR = 1.45; 95% CI, 1.20-1.80). CHW outreach and mobile units showed the largest effects. Feasibility was highest for CHW and culturally adapted strategies due to community trust, low costs, and adaptability.</p><p><strong>Conclusion: </strong>Community-based, culturally grounded interventions, particularly those integrating CHW networks and Indigenous leadership, significantly improve vaccination coverage among hard-to-reach populations in LAC. These findings support scaling equity-centered models within national immunization policies.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"14 ","pages":"25151355261472591"},"PeriodicalIF":0.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148674192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in HPV vaccination and their role in global cervical cancer control: a review.","authors":"Agapiti H Chuwa","doi":"10.1177/25151355261449446","DOIUrl":"10.1177/25151355261449446","url":null,"abstract":"<p><p>Cervical cancer remains a primary cause of gynecologic oncology-related mortality globally, with a disproportionate burden in sub-Saharan Africa. The pathogenesis of the disease is fundamentally driven by persistent infection with high-risk human papillomavirus (HPV) genotypes, most notably HPV-16 and HPV-18. The evolution of prophylactic HPV vaccination has transformed preventive oncology, progressing from first-generation bivalent and quadrivalent formulations to the nonavalent vaccine, which extended protection to five additional oncogenic types. These vaccines, composed of L1 virus-like particles (VLPs), induce robust and durable humoral and cellular immune responses, leading to population-level reductions of up to 98% in vaccine-type infections and 80% in high-grade cervical lesions. To address persistent global health disparities, regionally produced, cost-effective alternatives such as Cecolin and Cervavac have been introduced to enhance accessibility within low- and middle-income countries. This shift toward broader coverage is further supported by the 2022 WHO recommendation for a single-dose schedule, aimed at optimizing resource-limited immunization programs. Current research is now pivoting toward next-generation candidates targeting the conserved L2 protein for pan-genotype protection, as well as therapeutic vaccines targeting E6 and E7 oncoproteins to clear established infections. However, achieving the WHO's 2030 cervical cancer elimination targets remains contingent upon overcoming infrastructural, cultural, and informational barriers that hinder vaccine uptake. This review synthesizes the molecular composition and immunological mechanisms of current and emerging HPV vaccines, evaluating their clinical efficacy and the systemic strategies required to ensure equitable global access.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"14 ","pages":"25151355261449446"},"PeriodicalIF":0.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring supplemental immunization strategies to reach zero-dose children in low- and middle-income countries: a scoping review.","authors":"Andrea C Carcelen, Molly Sauer, Pooja Sangha, Porcia Manandhar, Natalya Kostandova, Alex C Kong, Rachel Larson, Rupali J Limaye, William J Moss","doi":"10.1177/25151355261442364","DOIUrl":"10.1177/25151355261442364","url":null,"abstract":"<p><strong>Background: </strong>Nationwide measles immunization campaigns are resource-intensive yet can fail to reach the same children who are not reached by routine immunization services. Alternative approaches to better reach missed communities and improve efficiency focus on identifying and reaching unvaccinated, \"zero-dose\" children. Understanding the scope and impact of these strategies can inform approaches to fill immunity gaps and reduce measles disease burden.</p><p><strong>Objectives: </strong>We conducted a scoping review to map the existing literature on supplemental strategies used to reach zero-dose or under-vaccinated children in low- and lower-middle-income countries (LLMICs).</p><p><strong>Eligibility criteria: </strong>Our review focused on the \"reach\" component of the Identify-Reach-Monitor-Measure-Advocate (IRMMA) framework. We included literature describing vaccination interventions for measles-rubella, polio, and the Essential Program on Immunization (EPI) in LLMICs published from 2010 to 2021 in multiple languages. We excluded papers that solely focused on non-selective national vaccination campaigns.</p><p><strong>Sources of evidence: </strong>We searched peer-reviewed databases (PubMed, WorldWideScience, and Scopus) and gray literature in World Health Organization (WHO) regional databases, the WHO Institutional Repository for Information Sharing, and John Snow, Inc. resource libraries.</p><p><strong>Charting methods: </strong>Screening and extraction were conducted in Covidence. We iteratively coded, classified, and analyzed extracted data. Interventions were classified into the IRMMA framework categories: demand generation, human resources, supply chain, and service delivery.</p><p><strong>Results: </strong>Of 9450 articles screened, 185 met criteria for inclusion in the final analytic set. Strategies consisted of enhancements to the routine immunization program, with service delivery being the most frequent, followed by demand generation. Many studies described the integration of multiple strategies, offering opportunities to maximize reach and impact.</p><p><strong>Conclusion: </strong>The vaccination strategies other than campaigns described in this review have been implemented in multiple countries; some demonstrate greater potential to reach zero-dose and under-vaccinated children. In the face of an evolving funding environment, prioritizing interventions that are most likely to reach unvaccinated children is key.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"14 ","pages":"25151355261442364"},"PeriodicalIF":0.0,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rabies post-exposure prophylaxis in India: a SWOT analysis.","authors":"Geeta Pardeshi, Priyanka Sharma, Anjana Ittiel","doi":"10.1177/25151355251410780","DOIUrl":"10.1177/25151355251410780","url":null,"abstract":"<p><p>Rabies remains a pressing public health issue, particularly in countries like India, where it inflicts a significant toll on marginalised communities. With approximately 20,000 deaths annually due to rabies, the disease underscores the urgency for effective prevention strategies. Despite the existence of post-exposure prophylaxis (PEP), rabies continues to claim lives, highlighting the importance of understanding and addressing the challenges in its implementation. This study aims to conduct a comprehensive analysis of strengths, weaknesses, opportunities and threats (SWOT) of India's rabies PEP programme, emphasising the urgent need for enhanced strategies to combat this preventable yet incurable disease. A thorough review of scientific literature, governmental guidelines, programme documents and media reports related to rabies and PEP was undertaken. The SWOT matrix was employed to categorise the identified factors influencing PEP administration. The analysis revealed both strengths and weaknesses inherent in the current PEP programme. Despite the availability of effective biological products and political commitment, challenges such as inadequate inventory management, delayed dissemination of guidelines, poor awareness, inadequate infrastructure and budgetary constraints persist. However, opportunities for improvement, including information dissemination and technological innovations, were identified. Threats such as pandemics and misleading media reports pose additional challenges to rabies control efforts. By emphasising the preventable yet incurable nature of rabies and highlighting the annual toll it exacts on human lives, this study underscores the urgency for effective and coordinated public health interventions to achieve the goal of dog-mediated rabies elimination by 2030. The findings underscore the critical importance of addressing weaknesses and capitalising on opportunities to strengthen rabies control strategies in India. Proactive measures are essential to enhance inventory management, ensure guidelines' dissemination, improve awareness levels, strengthen infrastructure and leverage technological advancements. Additionally, addressing threats such as pandemics and media misinformation requires collaborative efforts and proactive risk communication strategies. Through a targeted approach focused on enhancing rabies PEP implementation along with other measures such as community engagement to build awareness about rabies, and canine vaccination, including mass dog vaccination, India can significantly reduce the burden of rabies-related mortality.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"14 ","pages":"25151355251410780"},"PeriodicalIF":0.0,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12759123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145901205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the safety and immunogenicity of the VLA15 vaccine among healthy or high-risk population: a systematic review and meta-analysis of randomized controlled trials.","authors":"Tayyaba Naseem Abbasi, Muhammad Saad Khan, Erum Siddiqui, Muhammad Ahmed Zaheer, Areeba Tabassum, Naila Zainab, Aminath Waafira","doi":"10.1177/25151355251387927","DOIUrl":"10.1177/25151355251387927","url":null,"abstract":"<p><strong>Background: </strong>Lyme disease, the most common vector-borne illness in the Northern Hemisphere, is caused by Borrelia burgdorferi and transmitted via tick bites. With rising global incidence and no approved human vaccine, VLA15, a novel recombinant vaccine targeting six OspA serotypes, shows promise as an effective preventive strategy.</p><p><strong>Objective: </strong>This study aims to assess the safety and immunogenicity of the VLA15 vaccine among healthy or high-risk populations.</p><p><strong>Design: </strong>We conducted a systematic review and meta-analysis of three randomized controlled trials.</p><p><strong>Methods: </strong>This systematic review and meta-analysis, registered in PROSPERO (CRD420251058818), was conducted following PRISMA guidelines. A thorough search of PubMed, EMBASE, Cochrane Library, Scopus, ScienceDirect, and ClinicalTrials.gov was performed up to May 2025. Data extraction and quality assessment (using Cochrane ROB 2) were performed independently by reviewers. Risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models.</p><p><strong>Results: </strong>Three RCTs, including 5907 participants (4500 VLA15; 1407 placebo), met inclusion criteria. VLA15 recipients showed a significantly higher risk of adverse events: fever (RR 2.65, 95% CI: 1.77-3.96), headache (RR 1.40, 95% CI: 1.21-1.62), fatigue (RR 1.33, 95% CI: 1.15-1.55), and arthralgia (RR 2.50, 95% CI: 1.67-3.76), all with <i>p</i> < 0.0001. Subgroup analysis revealed a dose-response trend for arthralgia, particularly at 135 μg and 180 μg doses. However, nausea (RR = 1.34, <i>p</i> = 0.10) and severe unsolicited AEs (RR = 1.22, <i>p</i> = 0.42) were not statistically significant, suggesting no meaningful increase in these risks. Immunogenicity outcomes consistently favored VLA15, showing elevated IgG levels, GMTs, and seroconversion rates.</p><p><strong>Conclusion: </strong>VLA15 exhibits strong immunogenicity and acceptable safety, despite an increased risk of mild-to-moderate adverse events. Continued research and monitoring are warranted to support its use in Lyme disease prevention.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"13 ","pages":"25151355251387927"},"PeriodicalIF":0.0,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12575933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunization safety monitoring: addressing vaccine hesitancy and enhancing coverage in crisis-affected regions-insights from Lebanon, Ukraine, and Sudan.","authors":"Ramona Nasr, Eman Swaidan, Samah Hachem, Noura Yazbek, Mahdi Rizk, Abir Abdel Rahman, Nael H Alami","doi":"10.1177/25151355251380220","DOIUrl":"10.1177/25151355251380220","url":null,"abstract":"<p><p>Global vaccine hesitancy, intensified by crises such as the COVID-19 pandemic, represents a significant threat to immunization coverage. This narrative review discusses immunization safety monitoring frameworks and vaccine hesitancy in crisis-affected regions, particularly in Lebanon, Ukraine, and Sudan. By examining and reflecting on these case studies, this review aims to examine challenges, highlight context-specific strategies, and propose solutions for enhancing vaccine uptake and trust in fragile and conflict-affected areas. A structured narrative review was conducted, collecting evidence from global frameworks and region-specific case studies. The review explored factors impacting vaccine hesitancy, the role of adverse events following immunization (AEFI) monitoring systems, and innovative technological interventions. Key sources included peer-reviewed articles, reports from humanitarian organizations, and systematic reviews. The review showed that vaccine hesitancy is affected by interconnected factors, including sociopolitical and cultural conflicts, and misinformation. Lebanon's persistent economic and political instability, Ukraine's disruptions caused by the ongoing war, and Sudan's fragile healthcare infrastructure pose challenges to vaccine coverage. Successful interventions to address hesitancy included transparency in AEFI reporting, integration of real-time monitoring systems, and community-led initiatives. It is critical to mitigate vaccine hesitancy in crisis-affected regions through robust safety monitoring frameworks and tailored communication strategies. Global cooperation and frameworks, technological innovations, and context-specific approaches are imperative for improving the resilience of immunization systems and ensuring health security in fragile settings. Furthermore, these insights are crucial in informing public health communication policies and behavior change interventions to improve public trust and thus reduce vaccine hesitancy.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"13 ","pages":"25151355251380220"},"PeriodicalIF":0.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The urgent need for a licensed dengue vaccine in the Philippines.","authors":"Dalmacito A Cordero","doi":"10.1177/25151355251380216","DOIUrl":"10.1177/25151355251380216","url":null,"abstract":"","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"13 ","pages":"25151355251380216"},"PeriodicalIF":0.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uptake of human papillomavirus vaccination and associated factors among high school female students in Dessie City Administration, North East Ethiopia: a cross-sectional study.","authors":"Abdu Hussen, Nigusie Tadesse, Endalew Minwuye Andargie, Yonas Fissha Adem","doi":"10.1177/25151355251375970","DOIUrl":"10.1177/25151355251375970","url":null,"abstract":"<p><strong>Background: </strong>The vaccination for human papillomavirus (HPV) is a widely acknowledged global measure aimed at preventing cervical cancer. However, the rate of vaccine adoption differs across various regions and countries due to a number of discouraging factors. Therefore, this study aimed to assess the uptake of HPV vaccination and associated factors among high school female students in Dessie City Administration, Northeast Ethiopia, 2023.</p><p><strong>Methods: </strong>School-based cross-sectional study was conducted among 410 high school female students in Dessie City Administration from April 1, 2023, to May 1, 2023. Participants were selected using a simple random sampling technique. The data were collected using self-administered questionnaires. Data were entered using EPI data version 4.6 and exported to SPSS version 26 for analysis. Data were presented with frequency tables, graphs, and pie charts. To determine the factors associated with the outcome, a two-step logistic regression approach was employed. Initially, a bivariable analysis identified potential predictor variables with a <i>p</i>-value of less than 0.25, which were then included in a multivariable model. A <i>p</i>-value of less than 0.05 and an adjusted odds ratio at a 95% confidence level were used to confirm associations. In addition, the Hosmer-Lemeshow test was used to assess the model's goodness of fit.</p><p><strong>Results: </strong>The overall uptake of the HPV vaccine among female high school students in Dessie City was 54.9% with 95% CI (50.2, 59.8). In this study finding, fathers' educational level (AOR = 5.00, 95% CI: (1.59, 15.73)), source of information (AOR = 2.08, 95% CI: (1.13, 3.83)), and having positive attitude toward HPV vaccination (AOR = 1.88, 95% CI: 1.23, 2.87) were variables that showed a significant association with uptake of HPV vaccine.</p><p><strong>Conclusion: </strong>In this study, nearly half a percent of female high school students did not uptake the HPV vaccine. Fathers' education level, source of information, and positive attitude were positively associated with the uptake of the HPV vaccine among female high school students. Therefore, schools should provide continuous school-based training about the HPV vaccine to foster attitudinal change among female high school students.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"13 ","pages":"25151355251375970"},"PeriodicalIF":0.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145114237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}